© PR Newswire
07.12.2025
2171
LISTED
HKSE
CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue
News Preview
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully human BCMA-targeted CAR-T product, zevorcabtagene autoleucel (zevor-cel, R&D code: CT053), has...
Themefolio
Profiler
Peergroup
© PR Newswire
07.12.2025
9926
LISTED
HKSE
All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs
News Preview
HONG KONG, Dec. 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL) for 2025, released by China's National Healthcare Security Administration (NHSA), effective January 1, 2026...
Themefolio
Profiler
Peergroup
© BusinessWire
07.12.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Updates to China’s National Reimbursement Drug List
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA):
VYVGART® (efgartigimod alfa injection) is renewed for the treatment of adult patients with generalize...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
07.12.2025
NUVB
LISTED
NYSE
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
News Preview
SAN FRANCISCO and SUZHOU, China, Dec. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces t...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESSWIRE
07.12.2025
ONCO
LISTED
NEO
Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering
News Preview
VANCOUVER, BC / ACCESS Newswire / December 7, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has engaged a U.S. investment bank to serve as its capital markets advisor in connection with the Company's intention to pursue a potential...
Themefolio
Profiler
Peergroup
© PR Newswire
07.12.2025
ABT
LISTED
NYSE
University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives
News Preview
University of Wisconsin wins Abbott and the Big Ten Conference's "We Give Blood" drive, awards $1 million from Abbott to advance student or community healthSecond year of nationwide blood drive saw a 319% increase in overall participation with 83,043 donations and a 168% jump in student donors compared to 2024Big Ten students, alumni, and fans hel...
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2025
PFE
LISTED
NYSE
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
News Preview
Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. H...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
TCRX
LISTED
NASDAQ
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
News Preview
Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52)...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
FULC
LISTED
NASDAQ
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
News Preview
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at Week 6 (vs. 5.6% at Week 6 in the 12 mg cohort); 7 of 12 patients in the 20 mg cohort (58%) achieved absolute HbF levels ≥20% ―...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
BNTX
LISTED
NASDAQ
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
News Preview
Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard chemotherapy and a manageable safety profile in sqNSCLC...
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2025
ACLX
LISTED
NASDAQ
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
News Preview
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory mul...
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2025
GILD
LISTED
NASDAQ
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
News Preview
Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The results of the analysis were shared in an oral presentation (A...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
06.12.2025
GILD
LISTED
NASDAQ
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
News Preview
Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which continues to show clinically meaningful deep and durable efficacy with predictable and manageable safety observed to date in relapsed o...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
LEGN
LISTED
NASDAQ
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
News Preview
SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced new long-term clinical and translational data for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) from the CARTITUDE-1 and CARTITUDE-4 studies in relapsed / refractory multiple myeloma (RR...
Themefolio
Profiler
Peergroup
© PR Newswire
06.12.2025
HLUN A
LISTED
CPH
Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
News Preview
New long-term data presented at AES 2025 indicate reductions in seizure frequency are maintained for up to two years after treatment initiation with bexicaserin in patients with Developmental and Epileptic Encephalopathies (DEEs)1DEEs are a group of devastating, rare epilepsies characterized by unpredictable, drug-resistant seizures combined with...
Themefolio
Profiler
Peergroup
© PR Newswire
06.12.2025
HLUN A
LISTED
CPH
Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
News Preview
New long-term data presented at AES 2025 indicate reductions in seizure frequency are maintained for up to two years after treatment initiation with bexicaserin in patients with Developmental and Epileptic Encephalopathies (DEEs)1DEEs are a group of devastating, rare epilepsies characterized by unpredictable, drug-resistant seizures combined with...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
PRLD
LISTED
NASDAQ
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
News Preview
First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms...
Themefolio
Profiler
Peergroup
© PR Newswire
06.12.2025
JNJ
LISTED
NYSE
Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
News Preview
Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single infusion as early as second lineData suggest stronger immune fitness in earlier lines may be associated with longer progression free survivalORLANDO, Fla., Dec. 6, 2025 /PRNewswire/ -- Johnson &am...
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2025
TAK
LISTED
NYSE
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
News Preview
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. T...
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2025
GMAB
LISTED
NASDAQ
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
News Preview
Genmab A/S (Nasdaq: GMAB) today announced updated results from two ongoing clinical trials evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging antibody administered subcutaneously, as a monotherapy and in combination with other standard of care treatments in adult patients with diffuse large B-cell lymphoma (DLBCL) and follic...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
6855
LISTED
HKSE
Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting
News Preview
ROCKVILLE, Md. and SUZHOU, China, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization novel, differentiated therapies to address unmet medical needs in cancer, announced t...
Themefolio
Profiler
Peergroup
© PR Newswire
06.12.2025
VTRS
LISTED
NASDAQ
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
News Preview
Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon LimitedTransaction Accelerates the Expiration of Biosimilars Non-Compete RestrictionsPITTSBURGH, Dec. 6, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that it has entered into definitive agreements with Biocon Limited ("Biocon") for the sale of V...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
GMAB
LISTED
CPH
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
News Preview
Media ReleaseCOPENHAGEN, Denmark; December 6, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
NRIX
LISTED
NASDAQ
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual M
News Preview
Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
COGT
LISTED
NASDAQ
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
News Preview
-- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- -- Bezuclastinib demonstrates that reducing objective measures of disease, including serum tryptase, correlates with improvement in symptom severity; the first time thi...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
ADPT
LISTED
NASDAQ
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
News Preview
Adaptive announces deep interventional use of clonoSEQ across abstracts at ASH...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
ARVN
LISTED
NASDAQ
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
News Preview
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma (DLBCL); initiation expected in 2026 –...
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2025
VRTX
LISTED
NASDAQ
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clin...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
IRON
LISTED
NASDAQ
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
News Preview
WATERTOWN, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive initial data from the RALLY-MF Phase 2 trial of DISC-0...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
APTO
LISTED
NASDAQ
Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
News Preview
Aptose’s Tuspetinib Triple Drug Therapy Featured at 2025 ASH Annual Meeting;
High Rate of Frontline Clinical Responses Continues Across AML Population...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
BEAM
LISTED
NASDAQ
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
News Preview
Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Durable for up to 20 Months...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
BCAX
LISTED
NASDAQ
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
News Preview
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study interim analysis...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
1877
LISTED
HKSE
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
News Preview
Promising long-term survival results from toripalimab's JUPITER-02 and JUPITER-06 presented at the ESMO ASIA...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2025
ORIC
LISTED
NASDAQ
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
News Preview
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases...
Themefolio
Profiler
Peergroup
© PR Newswire
06.12.2025
NKTR
LISTED
NASDAQ
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN FRANCISCO, Dec. 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 18,310 shares of its common stock to two newly-hired employees under Nektar's 2025 Inducement Plan....
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2025
PRGO
LISTED
NYSE
PRGO ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Perrigo Company plc Investors
News Preview
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Perrigo Company plc (“Perrigo” or the “Company”) (NYSE:PRGO) securities during the period of February 27, 2023 through November 4, 2025, inclusive (“the Class Period”).
If you suffered a loss on your Perrigo investments, yo...
Themefolio
Profiler
Peergroup
© Newsfile
05.12.2025
PMED
LISTED
CSE
Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement
News Preview
Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, is pleased to announce that it has successfully closed the final tranche of its non-brokered private placement (the "Offering").In th...
Themefolio
Profiler
Peergroup
© Newsfile
05.12.2025
HEAL
LISTED
CSE
Restart Life Sciences Announces Closing First Tranche of Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") announces that further to its news release dated November 12, 2025, the Company has closed the first tranche of its non-brokered private placement for total gross proceeds of CDN$...
Themefolio
Profiler
Peergroup
© Newsfile
05.12.2025
MYTC
LISTED
CSE
Correction to MyndTec Inc. Press Release Issued December 3, 2025 Regarding Non-Brokered Private Placement
News Preview
Mississauga, Ontario--(Newsfile Corp. - December 5, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), announced today a correction to its press release titled "MyndTec Inc. Completes Eighth Tranche of Non-Brokered Private Placement" issued on December 3, 2025 (the "Initial Press Release").The Initial Press Release incorrectl...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 67,483 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
JNJ
LISTED
NYSE
Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
News Preview
New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removalPatients with this type of bladder cancer have limited choices beyond radical cystectomy, highlighting the need for newer therapies for bladder preservationRARITAN, N.J.,...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
News Preview
Vancouver, Canada, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced today that on December 4, 2025, the Com...
Themefolio
Profiler
Peergroup
© Newsfile
05.12.2025
CXXI
LISTED
CSE
C21 Investments Announces Renewed Normal Course Issuer Bid
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - C21 Investments Inc. (CSE: CXXI) (OTCQX: CXXIF) ("C21" or the "Company"), a vertically integrated cannabis company, is pleased to announce that it intends to commence a renewed normal course issuer bid (the "NCIB"), under which it may purchase up to 5,898,596 common shares of the Co...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
FULC
LISTED
NASDAQ
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee. Fulcrum...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
ORIC
LISTED
NASDAQ
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on December 1, 2025 (the “Grant Date”), ORIC granted a total of 69,200 non-qualified stoc...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
RGNT
LISTED
XASE
Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering
News Preview
Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial pub...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
TSHA
LISTED
NASDAQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
DALLAS, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on December 3, 2025, the Compensation C...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Grants of Inducement Awards
News Preview
WALTHAM, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Co...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4)....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
AVDL
LISTED
NASDAQ
Announcement relating to despatch of Rule 15 proposal
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
NTLA
LISTED
NASDAQ
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on December 1, 2025, it awarded inducement grants to three new employees under Intellia’s 2024 Inducement Plan as a mater...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
NAMS
LISTED
NASDAQ
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
NAARDEN, The Netherlands and MIAMI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
News Preview
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
ZEAL
LISTED
CPH
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
News Preview
Company announcement – No. 24 / 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
ANTM
LISTED
NYSE
Elevance Health Expands Virtual Assistant to Help Members Navigate Healthcare with Confidence
News Preview
Elevance Health announced today that it expanded access of its Virtual Assistant, a digital experience designed to help members easily access information, understand their benefits, and find care with confidence. Available through the Sydney Health app and Elevance Health–affiliated health plan websites, Virtual Assistant uses conversational techn...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
KALA
LISTED
NASDAQ
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
News Preview
ARLINGTON, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), a...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
SOBI
LISTED
STO
Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025
News Preview
STOCKHOLM, Dec. 5, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced its participation at the 65th American Society of Hematology (ASH) Annual Meeting, taking place on 6 – 9 December in Orlando, Florida. At this year's meeting, Sobi will showcase its commitment to advancing care in haematology with 19 scientific abstracts, including two oral...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
096530
LISTED
KOE
Seegene gründet Tochtergesellschaft in Frankreich und baut Präsenz in Europa weiter aus
News Preview
Seegene gründet Tochtergesellschaft in Frankreich und baut Präsenz in Europa weiter aus
Frankreich ist nach Italien und Deutschland die achte ausländische Vertriebsniederlassung von Seegene, sowie die dritte in Europa.
Das Land ist der zweitgrößte europäische Markt für molekulare Diagnostik, mit starker Nachfrage nach Tests für Magen-Da...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
096530
LISTED
KOE
Seegene Establishes French Subsidiary to Expand European Footprint
News Preview
- France becomes Seegene's eighth overseas sales subsidiary and third in Europe, following Italy and Germany- The country ranks as Europe's second-largest molecular diagnostics market, driven by demand in sexually transmitted infections and gastrointestinal testing, and respiratory virus detection.- The new subsidiary is expected to accelerat...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
CARM
LISTED
OTC
Carisma Announces Delisting from Nasdaq and SEC Deregistration
News Preview
PHILADELPHIA, Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed with the voluntary delisting of its common stock from The Nasdaq Stock Market LLC ("Nasdaq") and the deregistration of its common stock in order...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
